Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Aerocrine AB's share price for the quarter that ended in Mar. 2015 was kr1.034. Aerocrine AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2015 was 698.8 Mil. Therefore, Aerocrine AB's market cap for the quarter that ended in Mar. 2015 was kr722.5 Mil.
Aerocrine AB's quarterly market cap
stayed the same
from Sep. 2014 (kr0.0 Mil) to Dec. 2014 (kr0.0 Mil) but then
increased
from Dec. 2014 (kr0.0 Mil) to Mar. 2015 (kr722.5 Mil).
Aerocrine AB's annual market cap
increased
from Dec. 2012 (kr0.0 Mil) to Dec. 2013 (kr998.8 Mil) but then
declined
from Dec. 2013 (kr998.8 Mil) to Dec. 2014 (kr0.0 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Aerocrine AB's Enterprise Value for Today is kr1,778.4 Mil.
Aerocrine AB Market Cap Historical Data
The historical data trend for Aerocrine AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aerocrine AB's Market Cap
For the Medical Devices subindustry, Aerocrine AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aerocrine AB's Market Cap Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aerocrine AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Aerocrine AB's Market Cap falls into.
Aerocrine AB Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Aerocrine AB's Market Cap for the fiscal year that ended in Dec. 2014 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aerocrine AB (LTS:0O35) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Aerocrine AB Market Cap Related Terms
Thank you for viewing the detailed overview of Aerocrine AB's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Aerocrine AB is a medical technology company focused on improving the treatment of patients with inflamed airways. The company offers exhaled nitric oxide (NO) monitoring devices for research and clinical applications. Aerocrine's devices utilize methods for measuring minute concentrations of NO, and incorporate NO scrubbers to eliminate atmospheric NO from the patient's breath. Measuring NO values helps doctors differentiate asthma from similar conditions, and differentiate various forms of asthma from other airway diseases. The company markets two products globally namely NIOX Flex and NIOX MINO. These products are widely used by primary care asthma specialists in Europe, and have recently gained US regulatory approval. Distribution agreements have also been signed in Japan, and regulatory approval has been secured in China. The company has offices and subsidiaries in Sweden, Germany, the United States, and the United Kingdom. The parent company is located in Solna, Sweden, and has sales enterprises in Sweden, Germany, the United States, and the United Kingdom. NIOX was replaced by its successor, NIOX FLEX in 2007. NIOX FLEX was the first tailor-made device for measuring exhaled nitric oxide (NO). NIOX FLEX includes enhanced data handling facilities, add-on research kits, and USB ports for communication. Moreover, a new application, NIOX Flex Flow, can determine whether lung inflammation is located centrally or more peripherally, which can be highly significant to therapy choices. The Nasal Research Kit allows measurement of nasal NO, while the FlexFlo Research Kit enables measurement of exhaled NO at variable flow rates, to help identify the location of inflammation. NIOX MINO is a compact hand-held device, marketed for smaller clinics, healthcare centers, and hospitals. NIOX MINO is intended for routine measurements of NO. Patients hold the NIOX MINO and breathe into the mouthpiece. An audible tone helps patient maintain the right flow during exhalation, whereupon results are displayed on the front of the device.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0O35 has been successfully added to your 